Autonomix (AMIX) Medical recently participated in a Virtual Investor “What This Means” segment. For the segment, Dr. Robert Schwartz, CMO, discussed the Company’s recently announced 4-6 week positive follow-up data, from the first five “lead-in” patients in the Company’s ongoing proof-of-concept human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.